Merck withdraws Biologics License Application for Patritumab Deruxtecan

The decision to withdraw the BLA is based on topline overall survival (OS) results from the confirmatory HERTHENA-Lung02 Phase 3 trial where OS did not meet statistical significance

Aurobindo Pharma Q4 PAT falls marginally to Rs. 903 Cr

During the quarter, US formulations revenue increased by 13.5 per cent YoY to Rs. 4,072 crore

Strides Pharma Q4 net profit rises 5x to Rs. 113 Cr

For the full year FY25, net profit soared 12x to Rs 345 crore

Zydus receives final approval from USFDA for Isotretinoin Capsules USP

Isotretinoin capsules are indicated to treat severe, disfiguring nodular acne

Venus Remedies joins United Nations Global Compact

This global affiliation marks a critical step in the company’s mission to create long-term value through ethical practices, scientific innovation, and inclusive healthcare delivery

Tata 1mg optimises e-commerce operations with Unicommerce

Alembic Pharmaceuticals receives USFDA final approval for Rivaroxaban Tablets USP

Shelter Pharma launches three new products

Shelter Pharma Limited is set to capitalize on the growing demand for natural health products in India

Briefs: Zydus and CuraTeQ Biologics

CuraTeQ Biologics receives approval for biosimilar Zefylti from UK’s MHRA

Morepen Board proposed dividend after 23 years

Scores highest PAT of Rs. 118 crore in FY25